baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Sanofi SA/ FR0000120578 /

2024-04-19 4:26:32 PM	Chg. +1.210	Volume	Bid4:26:34 PM	Ask4:26:34 PM	Market Capitalization	Dividend Y.	P/E Ratio
86.440EUR	+1.42%	849,783 Turnover: 73.07 mill.	86.440Bid Size: 207	86.460Ask Size: 341	108.3 bill.EUR	4.35%	20.04

GlobeNewswire 04-17 IGM Biosciences Announces Refocusing of Sanofi Collaboration

GlobeNewswire 04-17 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...

GlobeNewswire 04-16 2024 DTA Summit Agenda is LIVE!!

GlobeNewswire 04-10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...

GlobeNewswire 04-09 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...

GlobeNewswire 03-29 Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire 03-22 Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

GlobeNewswire 03-14 MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Busi...

GlobeNewswire 03-14 SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors

GlobeNewswire 03-11 Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance ...

GlobeNewswire 03-05 Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (F...

GlobeNewswire 02-28 Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized ...

GlobeNewswire 02-27 Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...

GlobeNewswire 02-24 Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significa...

GlobeNewswire 02-23 Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” co...

GlobeNewswire 02-23 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...

GlobeNewswire 02-23 Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inf...

GlobeNewswire 02-22 Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoi...

GlobeNewswire 02-22 Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Bus...

GlobeNewswire 02-16 Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

GlobeNewswire 02-16 Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

GlobeNewswire 02-15 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corp...

GlobeNewswire 02-15 Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy ...

GlobeNewswire 02-05 Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global p...

GlobeNewswire 02-02 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Sanofi SA/ FR0000120578 /

If you wish to receive reply to your feedback, please provide your email address.